Lupin Ltd. Share Price

Lupin Launches World-First Triple Inhaler for COPD

Lupin: Triple-combination inhaler targets COPD demand

Lupin receives USFDA approval for injectable drug

Lupin Limited

Lupin Receives U.S. FDA Approval for Vitamin K Injection

Lupin Limited | Pharmaceutical Update Lupin Limited has received U.S. FDA approval for its Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL, in a single-dose prefilled syringe. **Key Highlights** * **Regulatory Milestone:** ANDA approved by the U.S. FDA. * **Product Application:** Used for the treatment and prevention of low blood clotting and vitamin K deficiency. * **Market Opportunity:** The product recorded estimated annual U.S. sales of **$52.3 million**, as per IQVIA MAT August 2026 data. * **Reference Product:** Bioequivalent to the product marketed by International Medication Systems, Limited. **Investor Insight** The approval strengthens Lupin’s U.S. generics portfolio and provides access to an established pharmaceutical market. However, the actual revenue contribution will depend on the product launch, market competition, pricing and market share. **Market View:** A positive regulatory development, with the financial impact dependent on commercial execution. *Disclaimer: For informational and educational purposes only. This is not investment advice. Investments in securities markets are subject to market risks.* Like | Share | Follow **AFS Trading Edge** for more corporate and market updates

Lupin gains US FDA approval for $52.3 million drug

Lupin Limited received US FDA approval for its vitamin K injection, a product with estimated annual US sales of $52.3 million. The approval expands its injectable drug portfolio in the US market. The company received approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL, in a single-dose prefilled syringe. The product is bioequivalent to the reference drug marketed by International Medication Systems. It is used to prevent and treat blood-clotting problems caused by vitamin K deficiency and hypoprothrombinemia. According to IQVIA MAT August 2026 data, the product recorded estimated annual US sales of $52.3 million. This provides Lupin with an opportunity to enter an established market, although actual revenue will depend on the commercial launch, pricing, competition and market share. The addressable market size should not be treated as guaranteed revenue for the company. Lupin also received US FDA approval for Sodium Zirconium Cyclosilicate for Oral Suspension in 5 g and 10 g packet strengths, as announced on August 10. The product is a generic equivalent of AstraZeneca's Lokelma and is indicated for treating hyperkalemia, or high potassium levels in adults. These approvals add to the company's US product pipeline across different therapeutic categories. My view: The vitamin K injection approval is a positive development, but the key factor is how much of the $52.3 million market Lupin can capture. I would watch for launch timelines, pricing pressure and further product approvals before assessing the financial contribution. Multiple approvals can support portfolio expansion, but their impact depends on execution and profitability. Lupin shares were trading at ₹1,962.60 on the NSE, up ₹25.70 or 1.33%. The next trigger to watch is the commercial rollout and any update on sales contribution.

Lupin Ltd holds ₹2,000, but the trend remains under pressure